← All trials
NCT05551182
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Jul 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- Sep 22, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ThailandLead sponsor
- Government of ThailandOverall official - principal investigator
- Government of ThailandStudy director
- Silpakorn UniversityCollaborator
- Burapha UniversityOfficial
- Government of ThailandOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.